SCHEMBL3614263

SCHEMBL3614263

c1cncc(-c2cncnc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 1.00
CYP3A4 P08684 3/20 0.79
ALDH1A1 P00352 2/20 0.79
CYP1A2 P05177 1/20 0.79
ATM Q13315 1/20 0.64
KDM4E B2RXH2 1/20 0.58
LMNA P02545 1/20 0.58
TP53 P04637 1/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 1/20 0.58
ALOX15 P16050 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HSD17B10 Q99714 1/20 0.58
MKNK1 Q9BUB5 4/20 0.54
MKNK2 Q9HBH9 4/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2B6 P20813 2/20 0.54
CYP2C19 P33261 1/20 0.54
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338888 1.00 CYP2A6 (1.00) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
Pyrimidine SCHEMBL28261125 0.92 CYP2A6 (0.85) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL28013979 0.91 CYP2A6 (0.83) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL6772005 0.89 CYP2A6 (0.88) CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E
SCHEMBL24492894 0.89 CYP2A6 (0.79) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL24493051 0.89 CYP2A6 (0.79) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL22428570 0.89 CYP2A6 (0.79) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL24554680 0.89 CYP2A6 (0.79) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL22428548 0.89 CYP2A6 (0.79) CYP2A6CYP3A4ALDH1A1CYP1A2ATM
SCHEMBL22428534 0.89 CYP2A6 (0.79) CYP2A6CYP3A4ALDH1A1CYP1A2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES BAXTER ANDREW 2010-04-01 US claimed
US-10930853-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2021-02-23 US disclosed
US-10573827-B2 Organic metal complex, and polymer, mixture, composition and organic electronic device containing same and use thereof GUANGZHOU CHINARAY OPTOELECTRONICS MATERIALS LTD. (CN) 2020-02-25 US disclosed
US-10364316-B2 Conjugated polymer containing ethynyl crosslinking group, mixture, formulation, organic electronic device containing the same and application therof GUANGZHOU CHINARAY OPTOELECTRONICS MATERIALS LTD. (CN) 2019-07-30 US disclosed
EP-3466932-A1 PRODUCTION METHOD FOR BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kobelco Eco-Solutions Co., Ltd (JP) 2019-04-10 EP disclosed
US-20180022865-A1 CONJUGATED POLYMER CONTAINING ETHYNYL CROSSLINKING GROUP, MIXTURE COMPOSITION, ORGANIC ELECTRONIC DEVICE CONTINAING THE SAME AND APPLICATION THEROF GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) 2018-01-25 US disclosed
US-20170365789-A1 COMPOUND, MIXTURE COMPRISING THE SAME, COMPOSITION AND ORGANIC ELECTRONIC DEVICE GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) 2017-12-21 US disclosed
US-9728805-B2 Nonaqueous electrolyte and lithium secondary battery using the same LG CHEM, LTD. (KR) 2017-08-08 US disclosed
US-9728805-B2 Nonaqueous electrolyte and lithium secondary battery using the same LG CHEM, LTD. (KR) 2017-08-08 US disclosed
US-20170155048-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-01 US disclosed
EP-2541663-A1 Nonaqueous electrolyte and lithium secondary battery using the same LG Chem, Ltd. (KR) 2013-01-02 EP disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES BAXTER ANDREW 2010-04-01 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
WO-2005066162-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP3A4 45/4885ALDH1A1 762/4885
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES CCL11, CCL2, CCR2 CYP2A6 1171/4885CYP3A4 1830/4885ALDH1A1 1544/4885
US-10573827-B2 Organic metal complex, and polymer, mixture, composition and organic electronic device containing same and use thereof OCIAD1, OCIAD2, SEM1 CYP2A6 652/4885CYP3A4 665/4885ALDH1A1 823/4885
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP3A4 45/4885ALDH1A1 762/4885
US-20170365789-A1 COMPOUND, MIXTURE COMPRISING THE SAME, COMPOSITION AND ORGANIC ELECTRONIC DEVICE DDT, DRD3, ICMT CYP2A6 1104/4885CYP3A4 198/4885ALDH1A1 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.